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Abstract 
Idiopathic pulmonary arterial hypertension (IPAH) is increasingly diagnosed in elderly 
patients who also have an increased risk of comorbid atherosclerosis.  Apolipoprotein E 
deficient (ApoE-/-) mice develop atherosclerosis with severe PAH when fed a high-fat diet 
(HFD), and have increased levels of endothelin (ET)-1. ET-1 receptor antagonists (ERAs) are 
used for the treatment of PAH but less is known about whether ERAs are beneficial in 
atherosclerosis. We therefore examined whether treatment of HFD-ApoE-/-  mice with 
macitentan, a dual ETA/ETB receptor antagonist, would have any effect on both 
atherosclerosis and PAH. ApoE-/- mice were fed chow or HFD for 8 weeks. After 4 weeks of 
HFD, mice were randomised to a 4-week treatment of macitentan by food (30mg/kg/day dual 
ETA/ETB antagonist), or placebo groups. Echocardiography and closed-chest right heart 
catheterisation were used to determine PAH phenotype and serum samples were collected for 
cytokine analysis. Thoracic aortas were harvested to assess vascular reactivity using wire 
myography, and histological analyses were performed on the brachiocephalic artery and 
aortic root to assess atherosclerotic burden. Macitentan treatment of HFD-fed ApoE-/- mice 
was associated with a beneficial effect on the PAH phenotype and led to an increase in 
endothelial-dependent relaxation in thoracic aortae.  Macitentan treatment was also 
associated with a significant reduction in interleukin 6 (IL-6) concentration but there was no 
significant effect on atherosclerotic burden. Dual blockade of ETA/ETB receptors improves 
endothelial function and improves experimental PAH but had no significant effect on 
atherosclerosis. 
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Introduction 
Idiopathic pulmonary arterial hypertension (IPAH) is a devastating life shortening condition 
1
. Although often thought to predominantly affect young women, recent data from the 
European COMPERA study highlights the increasing number of elderly patients over 65 
years of age diagnosed with IPAH 2. Atherosclerosis and atherosclerotic-associated diseases 
are the leading cause of cardiovascular disease and death worldwide 3,4. There are multiple 
risk factors for atherosclerosis including genetics, high levels of C-Reactive Protein and diet 
but the impact of more traditional risk factors such as high levels of triglyceride and LDL 
cholesterol, smoking and age still remains significant 5,6. Pro-inflammatory cytokines, such as 
those from the interleukin family, are upregulated in both atherosclerosis 7±9 and PAH 10,11. 
Specifically, overexpression of IL-6 in mice can lead to spontaneous PAH and exacerbates 
chronic hypoxia-induced PAH 12 and high IL-6 concentrations are also associated with 
increased mortality in patients with coronary artery disease and PAH 7,11,13. Interestingly, IL-
1 (sitting upstream of IL-6) is also elevated in both humans and animal models of PAH and 
atherosclerosis, and inhibition of IL-1 has shown therapeutic potential 8,10,14,15, indeed data 
from our own lab demonstrated therapeutic efficacy of IL-1 receptor antagonist treatment on 
the HFD-fed ApoE-/- model of PAH 16.  
Mechanistically, endothelial dysfunction is evident in both PAH and atherosclerosis in the 
form of impaired endothelium-dependent and ±independent vasorelaxation 17±19. ET-1 is a 
potent vasoconstrictor formed by the conversion of Big ET-1 to ET-1 by endothelin 
converting enzymes 20. ET-1 production and secretion can be regulated by inflammatory 
cytokines21,22, hypoxia and glucose 23±25, and is increased in the vessel wall of experimental 
models 26 and human atherosclerotic lesions 26,27 and PAH Reviewed in 28.  
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The biological function of ET-1 can be reduced through the administration of endothelin 
receptor antagonists (ERAs). ERAs bind to either one or both ETA/ ETB receptors on smooth 
muscle cells (SMC) or endothelial cells and reduce the vasoconstriction associated with ET-1 
29±31
. ERAs improve the prognosis of WHO functional class II and III PAH patients 32 and 
ETA-selective or dual ETA/ETB antagonism were shown to increase endothelial function and 
improve forearm 33,34 and coronary artery  35 blood flow in patients with atherosclerosis.   
Since atherosclerosis and PAH have these shared pathophysiological processes, and that ET-1 
stimulates production and secretion of IL-6 in human vascular SMCs via nuclear factor-ț%
(NF-ț%21, and with evidence of an aging population of IPAH patients, we sought to further 
investigate the potential impact of macitentan treatment on the Paigen HFD-fed ApoE-/-model 
of concomitant atherosclerosis and PAH 15,16. We hypothesised that treatment with a dual 
ERA would improve endothelial function, reduce inflammatory cytokines, improve cardiac 
hemodynamics and thus alleviate atherosclerotic lesion burden.  
Methods 
Animals 
ApoE-/- mice were obtained from Jackson Laboratories (Bar Harbor, ME) and were on a 
C57BL/6J background. Male mice weighing between 22 - 30 grams at 12 weeks of age were 
fed a high-fat, high-cholate Paigen diet (HFD; 18.5% fat, 0.9% cholesterol, 0.5% cholate, and 
0.2959% sodium) or standard chow (4.3% fat, 0.02% cholesterol and 0.28% sodium). Diets 
were supplied by Special Diet Services, Braintree, UK. At 16 weeks of age mice fed a Paigen 
diet (HFD) were randomised to either intervention (ApoE-/- HFD macitentan; 30 mg/kg/day) 
or treatment-naïve group (ApoE-/- HFD) for a further 4 weeks (n= 10/group). Mice fed a 
standard diet were treatment-naïve (ApoE-/- chow). All procedures conformed to UK Home 
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Office Regulations (Animals Scientific Procedures Act 1986; Project license 40/3517) and 
were approved by the University of Sheffield Project Review Committee.  
Echocardiography 
At week 20, transthoracic echocardiography was performed (n= 8/group) using the 
RMV707B scan head on the Vevo 770 system (VisualSonics, Toronto, Canada). There was a 
single operator blinded to the intervention status of the mice. Mice were placed on a heated 
platform with rectal temperature, heart rate and respiration rate monitored continuously. 
Anaesthesia was induced and maintained using isoflurane through oxygen. Right ventricular 
free wall and left ventricular parameters were obtained as previously described 36. Cardiac 
output was derived by measurement of the flow and diameter at the junction between aortic 
outflow tract and aortic valve. Cardiac index was normalised by body weight and all 
measurements were taken at non-inspiratory phase of the cardiac cycle. Analysis was 
performed using the Vevo 770 V3.0 VisualSonics software. 
Cardiac catheterisation 
Immediately after echocardiography, animals were maintained under 1-2% isoflurane whilst 
performing right and left ventricular catheterisation via either the right internal carotid artery 
or the right external jugular vein. Pressure-volume (PV) data were collected by Millar ultra-
miniature catheters (PVR-1045; mouse LV, PVR-1030; mouse RV: Millar Instruments, Inc., 
Houston, TX) coupled to a Millar MPVS 300. Data was acquired using Powerlab 8/30 (AD 
instruments, Oxfordshire, UK) and recorded using LabChart 7 Pro software (AD 
instruments). PVAN v2.3 (Millar Instruments, Inc.) was used to analyse PV data as 
previously described 36. 
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Assessment of right ventricular hypertrophy. 
Following cardiac catheterisation animals were euthanised by cervical dislocation under 2% 
isoflurane. Cardiac tissue was collected and fixed in 10% neutral buffered formalin for 24 
hours and washed with PBS. Using a modified Fulton index 37 weight of the right ventricle 
free wall relative to the left ventricle and septum was used to determine an estimate of right 
ventricular hypertrophy (n= 7/group). 
Endothelial function of thoracic aortae 
Mounting. Thoracic aortas from HFD-fed mice were harvested to assess vascular reactivity 
using wire myography (ApoE-/- HFD macitentan n= 4; ApoE-/- HFD n= 4 mice). Aortae were 
mounted onto a Danish Myo Technologies 610M wire myograph (DMT, Denmark), warmed 
to 37°C, and gassed with 95% air/5% CO2/balance N2 for 30 minutes in physiological salt 
solution (PSS in mM; 119 NaCl, 25 NaHCO3, 4.7 KCl, 1.17 MgSO4, 1.6 CaCl2, 1.17 
KH2PO4, 5.5 glucose, 0.03 EDTA (free acid) at pH 7.4).  
Normalisation. Incremental stretch was applied to each vessel using the micrometer attached 
to the myograph chamber and passive tension was recorded for 30 minutes until a passive 
steady resting tension of 5 mN was achieved.  
Experimental procedure. Post-equilibration, aortas were exposed to two separate washes with 
depolarizing solution (KPSS in mM: 63.7 NaCl, 25 NaHCO3, 60 KCl, 1.17 MgSO4, 1.6 
CaCl2, 1.17 KH2PO4, 5.5 glucose, 0.03 EDTA (free acid) at pH 7.4). After washing with PSS, 
aortas were pre-contracted with 10 µM phenylephrine and exposed to ACh (1x10í9 ± 
3x10í5 M). After washing with PSS, vessels were pre-contracted with 10 µM phenylephrine 
and exposed to the nitric oxide donor sodium nitroprusside (SNP; 1x10í9 ± 3x10í5 M). 
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Immunohistochemistry  
Left lung was perfusion fixed via the trachea as previously described 32. Briefly, left lung was 
inflated with 10% neutral buffered formalin at 20 cm of H2O. Lungs were processed in 
paraffin wax and sectioned (5 µm). Sections were histologically stained with Alcian Blue 
(ODVWLQYDQ*LHVRQ$%(9*)RULPPXQRKLVWRFKHPLVWU\VHFWLRQVZHUHVWDLQHGZLWKĮ-
smooth muscle actin (SMA; M0851; Dako, Cambridgeshire, UK) for smooth muscle cell 
identification and von Willebrand factor (vWf; A0082; Dako) to identify endothelial cells. 
Standard immunohistochemical techniques were applied, and both IgG and no primary 
antibody negative controls were used. The Axiocam 506 Color System (Zeiss) was used for 
microscopy and analysis was performed in Zen 2 Blue Edition (Zeiss). 
Quantification of pulmonary vascular remodelling 
The degree of pulmonary muscularisation was assessed and analysed as a percentage of total 
non-muscularised vessels 36. Vessels were categorised into two groups based on their size; 
small arterioles (<50 µm in diameter) and medium pulmonary arteries (>51 - <100 µm). 
Assessment of atherosclerotic lesion burden 
Aortic sinus paraffin-embedded sections were stained with ABEVG to assess mean lesion to 
cross sectional area ratio and martius scarlet blue to assess collagen content. Sections were 
DOVRVWDLQHGLPPXQRKLVWRFKHPLFDOO\ZLWKĮ-SMA, as described above. Whole mount aortae, 
which included aortic arch and descending aorta were stained with Oil Red O (Sigma, UK) to 
assess lesion area as a percentage of total aortic area. Scoring was performed in a blinded 
manner.  
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Enzyme linked immunosorbent assays 
Prior to sacrifice a cardiac puncture was performed and serum samples were collected for 
cytokine analysis (n=4±9/group). To assess concentration of soluble cytokines the Cytometric 
Bead Assay Flex sets (BD Biosciences, Oxford, UK) for Insulin, IL-ȕ,/-6, IL-10, HGF, 
TNF-Į0&3-1, Leptin, IP-10, SDF-1a and CRP was used. 
Statistical analyses 
When comparing two groups a Mann-Whitney U Test was used for statistical analyses. When 
comparing the medians of three groups or more a Kruskal-Wallis test followed by Dunns 
post-hoc test (95% confidence interval) was undertaken. For myography data in thoracic 
aortae two-way analysis of variance was performed with Bonferroni post-hoc test. P< 0.05 
was deemed to be significant (Prism 6.0; Graphpad Software). Data are presented as mean ± 
SEM, unless otherwise stated. For technical reasons certain procedures were unable to be 
completed on each individual animal and thus there is variation in the number of data points. 
An inability to quantify pulmonary artery flow using echocardiography, inability to 
catheterise left ventricle and a serum sample out of detection range of standard curve were 
the most common reasons for missing data. 
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Results 
Macitentan improves cardiac haemodynamics associated with PAH phenotype in HFD-fed 
ApoE-/- mice. HFD-fed ApoE-/- developed a PAH phenotype similar to that previously 
described 16,36 as assessed by a decrease in pulmonary artery acceleration time (PA-AT, 
Figure 1A), increase in right ventricular systolic pressure (RVSP, Figure 1B) and changes in 
right ventricular function (Figure 1C-D). Treatment with macitentan significantly increased 
PA-AT (Figure 1A), reduced RVSP (23 mm Hg vs. 38 mm Hg, Figure 1B) and improved RV 
function (Figure 1C-D). There was no effect of macitentan on left ventricular (LV) cardiac 
output (Figure 1E),  mean aortic blood pressure (Figure 1F) or LV end-diastolic pressure 
(LVeDP, Figure 1G). As previously reported 16,36, there was no significant increase in right 
ventricular hypertrophy (RVH) in HFD-fed ApoE-/- mice, and there were no significant 
differences in macitentan treated HFD-fed ApoE-/- when compared with treatment-naïve 
ApoE-/- mice (data not shown).  
 
Macitentan reverses pulmonary vascular remodelling associated with the PAH phenotype in 
HFD-fed ApoE-/- mice. Histologic and immunohistochemistry analysis of serial lung tissue 
sections revealed significant pulmonary vasculopathy consistent with a PAH phenotype in 
HFD-fed ApoE-/- mice. Analysis of media/CSA ratio in small resistance pulmonary arterioles 
<50 µm in diameter (Figure 2A) and the small to medium 51-100 µm pulmonary arteries 
(Figure 2B) demonstrated significant muscularisation in treatment-naïve HFD-fed ApoE-/- 
animals when compared to standard chow-fed ApoE-/- mice. Treatment with macitentan 
resulted in a significant decrease in the media/CSA for both the small pulmonary arterioles 
(<50 µm, Figure 2A&E), and the small to medium sized pulmonary arteries (51-100 µm, 
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Figure 2B). Similarly, there was a significant increase in the percentage of muscularised 
arterioles (< 50 µm, Figure 2C&E) and arteries (51 ± 100 µm, Figure 2D) in HFD-fed ApoE-/- 
mice that was also reduced by treatment with macitentan.   
 
Macitentan improves endothelial-dependent vascular function associated with 
atherosclerotic phenotype in HFD-fed ApoE-/- mice. In thoracic aortae explanted from 
macitentan treated HFD-fed ApoE-/- mice, endothelial-dependent relaxation of pre-contracted 
thoracic aortas was markedly increased compared to untreated HFD-fed ApoE-/- mice (Figure 
3A). Conversely, when thoracic aortas were once again pre-contracted with phenylephrine 
there was no significant effect of sodium nitroprusside-mediated endothelial-independent 
relaxation in macitentan-treated animals compared with treatment-naïve littermates (Figure 
3B). There were no differences in maximal contraction to 60 mM high-potassium 
depolarising salt-solution or 10 µM phenylephrine between treatment-naïve and macitentan-
treated ApoE-/- littermates (data not shown).  
 
Macitentan treatment had no effect on atheroma lesion burden in HFD-fed ApoE-/- mice. On 
examination of explanted whole aortae stained en face with Oil Red O (ORO) there appeared 
to be a small but significant increase in lipid deposition in macitentan-treated animals (Figure 
4A&C). This appeared to be due to greater accumulation of lipid specific to the aortic arch 
region (Figure 4B) and not the descending aorta (data not shown). However 
immunohistological analysis of both the brachiocephalic artery (Figure 4D-E) and aortic root 
sinus (Figure 4F-I) demonstrated that there was no significant effect of macitentan treatment 
on atherosclerotic lesion burden or composition. Macitentan treatment did not alter the size of 
 11 
 
the lesion, as assessed by the ratio of lesion to cross sectional area (Figure 4D), or the content 
of SMA in the lesion of the brachiocephalic artery (Figure 4E) compared with sections from 
control mice. Further histological assessment of the aortic root sinus also showed no 
significant change in the ratio of lesion to cross sectional area (Figure 4F&I), collagen 
content (Figure 4G&I) or vascular smooth muscle cell content (Figure 4H&I) of macitentan 
treated mice compared with treatment-naïve controls.  
 
Macitentan decreases IL-6 levels in HFD-fed ApoE-/- mice. Treatment with macitentan 
resulted in a significant reduction in circulating levels of IL-6 (Figure 5A) and increased the 
concentration of leptin (Figure 5B) in serum. There were no significant differences in TNF-Į
MCP-1, IL-ȕ,/-10, IP-10, SDF-1, CRP, Insulin or HGF (Figure 5C-K). 
 
Discussion 
To our knowledge, this is the first time macitentan has attenuated established PAH in mice. 
In a novel model of concomitant PAH and atherosclerosis, we found a significant reduction 
in muscularisation of small vessels and associated improvements in haemodynamics. Our 
results are consistent with pre-clinical studies using other models of pulmonary hypertension 
38
 and with clinical studies in PAH patients 32. Macitentan treatment increased endothelium-
dependent dilatation but was not associated with a reduction in atherosclerosis lesion burden 
at the aortic root or the brachiocephalic artery.  
The full molecular mechanisms by which ERAs attenuate PAH are still not fully understood, 
although there is clear evidence for vasodilatory effects that may result in flow-mediated 
improvements in remodelling. However, we also found a significant reduction in circulating 
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IL-6 in macitentan treated Paigen diet-fed ApoE-/- mice. Preclinical 12 and clinical 10,11 studies 
identify IL-6 as potentially a key regulator of PAH pathogenesis and therefore a putative drug 
target. Indeed, the direct effect of targeting IL-6 in PAH will soon become clearer with the 
conclusion of the TRANSFORM-UK study (NCT02676947). Studies by McMillen have 
previously demonstrated that ET-1 can stimulate IL-6 production from human 
monocytes 39. We propose that the same is occurring in this model, driving increased 
IL-6 in the Paigen diet-fed ApoE-/- mice, and that levels fall following the addition of 
Macitentan. Previous studies have shown that administration of an IL-6R antagonist in 
patients at high risk of coronary artery disease led to a reduction in IL-6, an increase in 
endothelial function, induction of dyslipidaemia and an increase in total lipid plasma content 
40
. There is a suggestion that the dyslipidaemia as a result of reduced IL-6 may in fact be 
causing the lipid profile to alter to a more anti-inflammatory composition 41.  In our model, 
quantitative assessment of aortic sinus and brachiocephalic lesion burden suggested there 
were no differences in lesion size or content between treatment-naïve and macitentan-treated 
HFD-fed ApoE-/- mice. Oil red O staining of the uppermost surface of the aortic tree 
dissected from experimental animals suggested increased lipid rich areas in the treated 
mice. However, as this technique can be highly influenced by tissue preparation, and 
since the much more robust and accepted histological assessment of aortic root and the 
brachiocephalic artery did not show any significant difference, we conclude that 
Macitentan does not adversely affect experimental atherosclerosis in our joint model of 
PAH and atherosclerosis. Our data contrast with other animal studies demonstrating that 
either dual ETA/ETB, or selective ETA receptor antagonists reduce the development and 
progression of atherosclerosis in both Western diet-fed ApoE-/- - and Ldlr-/--deficient mice 42±
4442,44,4542±44
. We speculate that there may be two explanations for a lack of effect of 
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macitentan on atherosclerotic lesion burden in our study; the length of treatment may not 
have been sufficient and/or atherosclerotic lesion development and progression was more 
pronounced in our novel model compared with the traditional Western diet. However, 
consistent with studies assessing the effects of ERAs on clinical atherosclerosis 30,34,35, 
macitentan was able to increase endothelium-dependent relaxation of thoracic aortas. 
Our study utilised an 8-week fat-feeding regimen commencing at 3 months of age. While this 
is a similar age used in previous studies investigating the effect of ERAs on atherosclerosis 
42±4442,44,4542±44
, macitentan was only administered for the final 4 weeks of the model. In the 
context of atherosclerosis there seems little consensus on the length of treatment of ERAs; 
with some studies opting for a 6 ± 10-week treatment period 42,44,45 whilst others opting for a 
longer 30-week period 43.  We chose a 4-week treatment period as this is known to be 
beneficial in PAH 16 and as such we wanted to assess whether it could impact on 
atherosclerosis in our Paigen diet-fed model. Indeed, a recent study from Houde and 
colleagues showed that a 6-week treatment of macitentan was sufficient to reduce aortic 
lesion development in ApoE-/- mice after 17 weeks of traditional Western diet 42. However, it 
must be noted that there is a far greater atherosclerotic lesion burden in ApoE-/-  mice fed a 
Paigen diet when compared with ApoE-/- mice fed a traditional Western diet 15. Taken 
together, these data suggest either increasing the length of treatment or commencing 
treatment at an earlier stage in atherogenesis may reduce lesion burden or dampen the 
progression of atherosclerosis in our model. Indeed clinical data suggest that ERAs are only 
able to reduce plaque progression in coronary arteries at the early stages of atherosclerosis 
and in the presence of endothelial dysfunction 46.  
Macitentan treatment convincingly led to increased endothelium-dependent relaxation in 
aortae and a reduction in the pro-inflammatory cytokine IL-6. Serum IL-ȕZDVQRWDOWHUHG
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but this is unsurprising given the inherent difficulties in measuring this cytokine 47. In high-
risk patients with PAH and concomitant atherosclerosis, worsening endothelial function and 
raised inflammatory markers such as CRP and IL-6 are quantifiable; thus, our data suggest 
macitentan may be of most benefit to these patients. 
In summary, macitentan significantly reduced the main pathological features associated with 
PAH such as pulmonary vascular remodelling and cardiac dysfunction. Macitentan treatment 
was associated with increased endothelium-dependent relaxation in aortae, a surrogate 
marker of endothelial function. Using our model of advanced atherosclerosis, there was no 
effect of macitentan on atherosclerotic lesion burden and treatment did not alter the 
morphology or the stability of plaques within the aortic sinus or brachiocephalic artery. We 
therefore suggest that macitentan treatment is able to improve endothelial function, reduce 
inflammatory mediators, such as IL-6 but this did not translate through to reduced 
atherosclerosis in our study setting. Given the numerous successes of ERAs in experimental 
and clinical atherosclerosis, combined with our results suggesting improvements in 
endothelial function and markers of inflammation, we propose future studies should assess 
the effects of the current generation of ERAs, such as macitentan, in clinical atherosclerosis.  
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Figure Legends 
Figure 1. Macitentan treatment reduces haemodynamic indices of PAH in HFD-fed 
ApoE-/- mice. Bar graphs show (A) pulmonary artery acceleration time (PA-AT), (B) right 
ventricular systolic pressure (RVSP), (C) right ventricular arterial elastane (RVEa), (D) right 
ventricular dP/dtmax in mm Hg/s, (E) cardiac output, (F) mean aortic pressure (mAoP), (G) 
left ventricular end-diastolic pressure (LVeDP). A and F: Measures were made using 
Vevo 770 echocardiography v3.0. All other measures were made using closed chest cardiac 
pressure volume catheterisation. Bars represent mean ± SEM, n= 6 ± 20, individual animals 
represented by dots. A - G: Statistical differences between chow-fed ApoE-/-, HFD-fed and 
HFD-fed + macitentan was assessed by Kruskal-Wallis analysis of vDULDQFHZLWK'XQQ¶V
multiple comparison post-hoc test; *P< 0.05, **P< 0.01.  
Figure 2. Macitentan treatment reduces pulmonary vascular remodelling in HFD-fed 
ApoE-/- mice. Bar charts (A and B) illustrating the degree of medial wall thickening 
(identified by smooth muscle actin; SMA) as a ratio of total vessel size (SMA / CSA) in <50 
µm arteriole (A) and small to medium sized pulmonary arteries (B).  (C and D) represent the 
percentage muscularised and non-muscularised arterioles (C) and arteries (D). Representative 
images of ABEVG and SMA stained tissue (E); ABEVG and SMA stained images of 
pulmonary arteries from ApoE-/- mice that were fed either chow (top), HFD with no treatment 
(middle) and HFD with macitentan (bottom). Scale bar represents 100 µm. A and B: Bars 
represent mean ± SEM, n= 7. Kruskal-Wallis analysis of variance *P<0.05 ***P< 0. C and 
D: stars represent level of statistical significance when compared with chow-fed ApoE-/- mice; 
****P< 0.0001. Post hoc analysis shows statistical differences between macitentan-treated 
and treatment-naïve HFD-fed mice (P< 0.0001). 
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Figure 3. Macitentan treatment improves vascular function in thoracic aortae. Graphs 
show cumulative dose response curves to increasing concentrations of acetylcholine (A) or 
sodium nitroprusside (B) in thoracic aortae pre-contracted with 10 µM phenylephrine. Data 
are expressed as mean ± SEM and presented as a % of endothelium-dependent (A) or ±
independent (B) relaxation, n= 4. *P< 0.05, ***P< 0.001. Statistical differences between 
treated and untreated HFD-fed mice were assessed by two-way analysis of variance with 
Bonferroni post hoc analysis. 
Figure 4. Macitentan treatment does not alter the composition or atherosclerotic burden 
in HFD-fed ApoE-/- mice. Bar charts show Oil Red O stain as a % of total aortic area (A), 
and within the aortic arch as a % of total arch area (B). (C) Representative images of Oil Red 
O in control and macitentan-treated mice. (D) Bar charts show the ratio of atherosclerotic 
lesion area within the brachiocephalic artery normalised to cross sectional area, and (D) the 
Į-smooth muscle actin positive tissue within the brachiocephalic sections. (F) shows the 
ratio of lesion area to cross sectional area within the aortic root sinus, (G) % collagen content, 
and (HĮ-smooth muscle actin positive tissue in aortic root sections. Panel I shows 
representative aortic root histological sections from control and macitentan-treated HFD-fed 
ApoE-/- PLFHVWDLQHGZLWK$%(9*PDUWLXVVFDUOHWEOXHFROODJHQDQGĮ-smooth muscle 
actin. Bars represent mean ± SEM. Statistical differences between sections from treated and 
untreated mice were assessed by Mann-Whitney U test, n= 11 ± 12. individual mice are 
represented by dots. *P< 0.05. Statistical differences between groups were measured by 
Mann-Whitney U test. 
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Figure 5. Macitentan treatment induces changes in inflammatory plasma cytokines in 
HFD-fed ApoE-/- mice. Bar charts show the plasma concentration of (A) interleukin-6 (IL-6), 
(B) leptin, (C) interleukin-10 (IL-10), (D) interleukin 1 beta (IL-ȕE) monocyte 
chemoattractant protein 1 (MCP-1), (FWXPRUQHFURVLVIDFWRUDOSKD71)ĮG) hepatocyte 
growth factor (HGF), (H) insulin, (I) interferon-gamma-inducible protein-10 (IP-10), (J) 
stromal cell-derived factor 1 (SDF-1) and (K) C-Reactive protein (CRP). Bar graphs 
represent mean ± SEM, n= 4 ± 9 with individual animals represented by dots. *P< 0.05. 
Statistical differences were assessed by Mann-Whitney U test. 
 
 
 
 
